News
NPCUF
0.0010
NaN%
--
Weekly Report: what happened at NPCUF last week (0908-0912)?
Weekly Report · 09/15 10:18
Weekly Report: what happened at NPCUF last week (0901-0905)?
Weekly Report · 09/08 10:20
Weekly Report: what happened at NPCUF last week (0825-0829)?
Weekly Report · 09/01 10:16
Weekly Report: what happened at NPCUF last week (0818-0822)?
Weekly Report · 08/25 10:23
Weekly Report: what happened at NPCUF last week (0811-0815)?
Weekly Report · 08/18 10:18
Weekly Report: what happened at NPCUF last week (0804-0808)?
Weekly Report · 08/11 10:22
Weekly Report: what happened at NPCUF last week (0728-0801)?
Weekly Report · 08/04 10:24
Weekly Report: what happened at NPCUF last week (0721-0725)?
Weekly Report · 07/28 10:25
Weekly Report: what happened at NPCUF last week (0714-0718)?
Weekly Report · 07/21 10:18
Weekly Report: what happened at NPCUF last week (0707-0711)?
Weekly Report · 07/14 10:24
Weekly Report: what happened at NPCUF last week (0630-0704)?
Weekly Report · 07/07 10:19
Weekly Report: what happened at NPCUF last week (0623-0627)?
Weekly Report · 06/30 10:23
Weekly Report: what happened at NPCUF last week (0616-0620)?
Weekly Report · 06/23 10:18
Weekly Report: what happened at NPCUF last week (0609-0613)?
Weekly Report · 06/16 10:23
Weekly Report: what happened at NPCUF last week (0602-0606)?
Weekly Report · 06/09 10:23
Weekly Report: what happened at NPCUF last week (0526-0530)?
Weekly Report · 06/02 10:28
Weekly Report: what happened at NPCUF last week (0519-0523)?
Weekly Report · 05/26 10:28
Weekly Report: what happened at NPCUF last week (0512-0516)?
Weekly Report · 05/19 10:22
Weekly Report: what happened at NPCUF last week (0505-0509)?
Weekly Report · 05/12 10:23
Weekly Report: what happened at NPCUF last week (0428-0502)?
Weekly Report · 05/05 10:24
More
Webull provides a variety of real-time NPCUF stock news. You can receive the latest news about Allon Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About NPCUF
Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).